BridgeBio late-stage genetic disease therapies set for US launches by 2027
BridgeBio says BBP-418, encaleret, and infigratinib are set for US launches by 2027, supporting a pipeline that includes three approved medicines and late-stage candidates targeting rare genetic diseases.
BridgeBio said it has a broad pipeline of genetic disease therapies that includes three approved medicines and several late-stage candidates aimed at multi-billion dollar markets. The company said Attruby is leading with strong performance, while BBP-418, encaleret and infigratinib are set for US launches by 2027.